Alzet mini pump

Manufactured by Durect

The Alzet mini-pump is a compact, programmable infusion pump designed for laboratory research. It allows for the continuous and controlled delivery of small volumes of fluids or solutions directly to experimental subjects. The device is implantable and can be used to administer substances continuously over an extended period of time.

Automatically generated - may contain errors

Lab products found in correlation

Thrombin, by Merck Group (1 mentions) Focus 220, by Siemens (1 mentions) Albuterol sulfate, by Merck Group (1 mentions) Buprenorphine, by Reckitt Benckiser (1 mentions) D12492, by Jackson ImmunoResearch (1 mentions) Oxymax open circuit calorimeter, by Columbus Instruments (1 mentions) C57bl 6j dio mice, by Jackson ImmunoResearch (1 mentions)

6 protocols using alzet mini pump

Optimizing Argatroban Therapy for Ischemic Stroke

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

The protocol was approved by the IACUC at Cedars-Sinai Medical Center, following all national guidelines for the care of experimental animals. Male Sprague Dawley rats (n=37, 290g to 310g) were assigned randomly: saline or 1.4units/kg thrombin (Sigma) in 0.2ml administered intra-arterially (IA) over 120min, or 0.45mg argatroban (Axxora) in 0.2ml administered intravenously (IV) for 2 hours^{2 (link)}. We used our published methods for middle cerebral artery occlusion (MCAo), behavior, and histology^{6 (link)},^{1 (link),7 (link)}.
To determine the optimum therapeutic time window for treatment with argatroban, we randomly assigned 272 male Sprague-Dawley rats, as above, to receive IV saline or “low dose” (10mg/kg) or “high dose” (18mg/kg) argatroban over 24 hours by Alzet mini-pump (model 2001D, Durect Corp). Treatment effects were assessed using the standard quantal bioassay procedure, and TTC staining^{8 (link)}. Treatment groups were compared using a t-test of the respective ED₅₀s using a Bonferroni correction for multiple comparisons.

Lyden P., Pereira B., Che B., Zhao L., Lamb J., Le I.F, & Rajput P. (2014). Direct Thrombin Inhibitor Argatroban Reduces Stroke Damage in Two Different Models. Stroke; a journal of cerebral circulation, 45(3), 896-899.

+ Open protocol

+ Expand

FGF21 Effects on Brown Adipose Tissue

Check if the same lab product or an alternative is used in the 5 most similar protocols

20 male C57Bl6/J DIO mice aged 16 weeks, were administered vehicle or FGF21 at 0.1, 0.3, and 1 mg/kg/day continuously via surgically implanted mini-pump (Alzet® mini-pump (Model #2002, Durect Corporation) for 8 days. Mice were fasted overnight and [¹⁸F]-FDG PET was performed using a Siemens Focus 220 microPET at 60 minutes post [¹⁸F]-FDG injection (~47 MBq, iv). To minimize background BAT FDG uptake, animals were maintained at 29.5 ± 2 °C beginning at 18 hours prior to scanning and up until time of scan. During scanning, body temperature was maintained using a heat lamp. After scanning was completed, animals were immediately sacrificed and BAT was dissected out and counted to determine the FDG uptake per gram of tissue using a Wallac Wizard 1470 gamma counter. Regions of interest (ROIs) were drawn around BAT images to determine mean and max [¹⁸F]-FDG uptake then analyzed using Analyze Software (version 7.0, developed by Mayo Clinic). ROI-derived and tissue counting data were compared for correlation.

Bernardo B., Lu M., Bandyopadhyay G., Li P., Zhou Y., Huang J., Levin N., Tomas E.M., Calle R.A., Erion D.M., Rolph T.P., Brenner M, & Talukdar S. (2015). FGF21 does not require interscapular brown adipose tissue and improves liver metabolic profile in animal models of obesity and insulin-resistance. Scientific Reports, 5, 11382.

+ Open protocol

+ Expand

Tumor Xenograft Compound Administration

Check if the same lab product or an alternative is used in the 5 most similar protocols

In all the tumor xenograft studies, the compound of interest was administered either orally at 5 to 10 mL/kg utilizing the sterile 20G feeding needles (popper and sons, inc., NY) or via a subcutaneous Alzet mini-pump (DURECT Corporation, Cupertino, CA) infusion.

Zou H.Y., Friboulet L., Kodack D.P., Engstrom L.D., Li Q., West M., Tang R.W., Wang H., Tsaparikos K., Wang J., Timofeevski S., Katayama R., Dinh D.M., Lam H., Lam J.L., Yamazaki S., Hu W., Patel B., Bezwada D., Frias R.L., Lifshits E., Mahmood S., Gainor J.F., Affolter T., Lappin P.B., Gukasyan H., Lee N., Deng S., Jain R.K., Johnson T.W., Shaw A.T., Fantin V.R, & Smeal T. (2015). PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to 1st and 2nd generation ALK inhibitors in pre-clinical models. Cancer cell, 28(1), 70-81.

+ Open protocol

+ Expand

Glibenclamide Treatment for Traumatic Injury

Check if the same lab product or an alternative is used in the 5 most similar protocols

Intravenous glibenclamide was loaded 10 minutes after CCI or within 5 minutes of HS completion. High dose =10 μg/mouse and low dose = 20 μg/kg (1 ). Vehicle solutions contained everything except drug (Fixnal, DMSO, normal saline) (21 (link)). Subcutaneous infusions were continued for 7 d (0.4 µg/hr, Alzet mini-pump; Durect Corporation, Cupertino, CA) for both groups. Glibenclamide was the only treatment used in this study; no other treatments like hyperosmolar therapy were used.

Zusman B.E., Wu Y., Kochanek P.M., Vagni V.E., Janesko-Feldman K., Gerzanich V., Simard J.M., Karahalios K., Mihaljevic S., Raikwar S., Rani A., Rulney J., Desai S.M., Catapano J, & Jha R.M. (2022). Precision Effects of Glibenclamide on MRI Endophenotypes in Clinically Relevant Murine Traumatic Brain Injury. Critical Care Medicine, 51(2), e45-e59.

+ Open protocol

+ Expand

Chronic Albuterol Infusion in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mice were treated with albuterol (2, 4 or 8 mg/kg/day) infused steadily for 2-weeks via an Alzet minipump (model 1002; Durect Corporation, Cupertino, CA) that was implanted beneath the skin of the mid back on day 0 of the IgG injections. Albuterol sulfate (Sigma) was dissolved in sterile water (vehicle). To implant the pump, mice were anaesthetized with 1–3% isoflurane/oxygen. Mice received buprenorphine (0.03 mg/kg subcutaneously; Reckitt Benckiser, Australia) for analgesia at the completion of surgery and 24 h later, as previously described [31] (link).

Ghazanfari N., Morsch M., Tse N., Reddel S.W, & Phillips W.D. (2014). Effects of the ß2-Adrenoceptor Agonist, Albuterol, in a Mouse Model of Anti-MuSK Myasthenia Gravis. PLoS ONE, 9(2), e87840.

+ Open protocol

+ Expand

Thermoneutral Acclimation and FGF21 in Obese Mice

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

32, 21 week old, male C57BL6/J DIO mice were obtained from the Jackson Laboratories (Bar Harbor, ME), fed 60% high fat diet (Research Diets D12492). Mice were acclimatized for 2 weeks at 72 °F (ambient) then moved to 80 °F that is close to thermoneutral zone, to acclimate another week prior to baseline randomization and subsequent surgery. For experiments at ambient temperature, mice were housed at 72 °F throughout the study. Animals were allocated into 4 groups of n = 8 based on BW and glucose levels to achieve equal distribution of these parameters in each group. On day 0, all animals underwent surgery for the implantation of an Alzet® mini-pump (Model #2002, Durect Corporation) for continuous delivery of either vehicle (PBS) or 0.85 mg/kg/day native FGF21. The iBAT was surgically removed at the time of mini-pump implant in those mice allocated into the X-BAT groups. VO₂ and VCO₂ were measured for 24 hours of fed and 24 hours of fasted conditions using a comprehensive laboratory animal monitoring system (CLAMS) equipped with an Oxymax Open Circuit Calorimeter (Columbus Instruments, Columbus, OH) as previously described (n = 8/group)20 (link)30 (link). RT-PCR One-Step (Qiagen) was used to determine the expression of UCP-1 by standard PCR protocol.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!